Handa Therap Company Profile
What is the competitive landscape for HANDA THERAP
HANDA THERAP has one approved drug.
There are six US patents protecting HANDA THERAP drugs.
Summary for Handa Therap
| US Patents: | 6 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Handa Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-005 | Dec 5, 2023 | RX | Yes | Yes | 11,202,778 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | 11,298,356 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | 11,324,745 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-006 | Dec 5, 2023 | RX | Yes | No | 12,544,376 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-002 | Dec 5, 2023 | RX | Yes | No | 12,544,376 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Handa Therap | PHYRAGO | dasatinib | TABLET;ORAL | 216099-005 | Dec 5, 2023 | RX | Yes | Yes | 12,544,376 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Handa Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 4093379 | ⤷ Start Trial |
| Japan | 2023513444 | ⤷ Start Trial |
| Japan | 2026004291 | ⤷ Start Trial |
| Israel | 294928 | ⤷ Start Trial |
| Canada | 3168667 | ⤷ Start Trial |
| European Patent Office | 4714503 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Handa Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1169038 | 122013000012 | Germany | ⤷ Start Trial | PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH GEEIGNETE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-009 EU/1/06/363/010-011 EU/1/06/363/012-015 20061120 |
| 1169038 | CA 2013 00006 | Denmark | ⤷ Start Trial | PRODUCT NAME: DASATINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER MONOHYDRATET; REG. NO/DATE: EU/1/06/363/001-015 20061122 |
| 1169038 | 2013C/005 | Belgium | ⤷ Start Trial | PRODUCT NAME: DASATINIB SOUS TOUTES FORMES COUVERTES PAR LA PROTECTION DU BREVET DE BASE INCLUANT LES SOLVATES, LES HYDRATES, TEL QUE LA FORME MONOHYDRATEE, ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/06/363/001 20061122 |
| 1169038 | 1390004-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: DASATINIB OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/06/363/001 20061120 |
| 1169038 | 6/2013 | Austria | ⤷ Start Trial | PRODUCT NAME: DASATINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120 |
| 1169038 | 2013/003 | Ireland | ⤷ Start Trial | PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
